Affimed N.V. AFMDQ

Searches for Affimed N.V. (AFMD) have surged today, indicating heightened interest in the biotech stock. This spike in searches may reflect investor sentiment or reactions to recent developments in the biotech sector, potentially impacting market performance. Increased search interest may influence market sentiment and trading activity, but the overall effect on the company's trajectory is expected to be limited.

Affimed N.V. has received a notice from Nasdaq indicating that its common shares will be suspended from trading on May 20, 2025, following the company's insolvency filing in Mannheim, Germany. The Nasdaq Listing Qualifications Department cited public interest concerns, the equity interests of existing shareholders, and the company's ability to comply with listing requirements as reasons for the delisting. Affimed does not plan to appeal this decision. The insolvency filing and subsequent delisting from Nasdaq fundamentally undermine the company's financial stability and market position.

Affimed N.V. has announced its decision to file for the opening of insolvency proceedings, indicating significant financial distress. The company is seeking to restructure its operations and liabilities in hopes of continuing its business activities. This move comes amid ongoing challenges in the biotechnology sector, impacting investor confidence and the company's future prospects. Filing for insolvency proceedings represents a critical juncture that could fundamentally redefine the company's competitive position and long-term viability.

Affimed N.V. presented findings at the AACR Annual Meeting showing that higher exposure to its drug AFM24 in patients with refractory non-small cell lung cancer (NSCLC) is linked to significantly improved response rates and progression-free survival. In a study of 72 patients, those with higher drug exposure had an objective response rate of 33.3% compared to 5.6% for those with lower exposure. The median progression-free survival was 7.3 months versus 2.9 months. The company plans to incorporate a 720 mg weekly dose of AFM24 in future trials to optimize clinical benefits and reduce early progression risk, as this dosage achieves target exposure levels quickly. These results support the potential of AFM24 as a novel treatment approach for advanced NSCLC. The findings indicate a significant correlation between drug exposure and clinical outcomes, suggesting a major strategic move in treatment protocols.

Affimed N.V. announced the acceptance of three abstracts for presentation at the American Society for Clinical Oncology Annual Meeting from May 30 to June 3, 2025. An oral presentation will focus on the phase 2 LuminICE-203 study of acimtamig combined with AlloNK in relapsed or refractory classical Hodgkin lymphoma. Two poster presentations will cover AFM24 in combination with atezolizumab for non-small cell lung cancer, one for patients without driver mutations and another for those with EGFR mutations. Full abstracts will be published online on May 22, 2025. The acceptance of multiple abstracts at a major oncology conference indicates significant progress in clinical development and could enhance investor sentiment and market positioning.

Affimed N.V. received a notice from Nasdaq indicating that its common shares have closed below the minimum bid price of $1.00 for 30 consecutive business days. The company has until October 13, 2025, to regain compliance with the Minimum Bid Price Rule. If compliance is not achieved, Affimed may apply to transfer its securities to the Nasdaq Capital Market for an additional 180 days to meet the requirement. The notice does not immediately affect the listing or trading of the shares. Affimed plans to monitor its share price and explore options for compliance. Non-compliance with the Minimum Bid Price Rule may affect investor sentiment and market performance.

Affimed N.V. announced the acceptance of an abstract regarding AFM24, focusing on dose optimization, for presentation at the American Association for Cancer Research Annual Meeting. This presentation is expected to highlight advancements in the company's cancer treatment research. The acceptance of the abstract indicates progress in product innovation, which may positively influence investor sentiment and the company's competitive positioning.

Affimed Shares Fall 32% on Clinical Update. Significant impact likely on future and performance due to the substantial drop in share price.

Affimed N.V. reports positive clinical update on AFM24/atezolizumab combination therapy in NSCLC patients, showing promising results in both EGFR wild-type and mutant cohorts. The positive clinical update and exposure-response analysis results are expected to significantly impact Affimed N.V.'s future development program and market performance.

Affimed N.V. reports promising Phase 1 efficacy and safety data for AFM28 in relapsed/refractory acute myeloid leukemia, achieving a 40% composite complete remission rate at the highest dose level. The significant milestone of achieving a 40% composite complete remission rate in a difficult-to-treat patient population is expected to have a major impact on Affimed N.V.'s future and market performance.

Affimed to host investor conference call highlighting clinical data from AFM24 in combination with Atezolizumab in non-small cell lung cancer. The release of positive clinical data in combination with a key drug like Atezolizumab could have a significant impact on Affimed N.V.'s future prospects and market performance.

Positive results of Acimtamig and AlloNK® combination in R/R cHL patients announced by Affimed N.V. (AFMD). The positive results demonstrating safety and efficacy of the combination therapy could significantly alter the company's trajectory and investor sentiment.

FDA grants RMAT status to AFMD's acimtamig combo therapy for R/R HL, shares initially down but rebound in after-hours trading. FDA's RMAT designation and promising early efficacy data for acimtamig combo therapy could significantly impact AFMD's future and market performance.

FDA grants RMAT designation to Affimed and Artiva's combo therapy for lymphoma, showing promising early efficacy data. The RMAT designation and positive early efficacy data are expected to significantly impact Affimed's future trajectory and market performance.

FDA grants RMAT designation to Affimed's acimtamig and AlloNK® combination therapy for R/R HL based on promising early efficacy data. The RMAT designation and positive efficacy data are expected to significantly impact Affimed's future trajectory and market performance.

Affimed N.V. (AFMD) is a biopharmaceutical company in the clinical stage, leading in the field of immuno-oncology with a strong product pipeline and positive clinical data updates. The article highlights significant clinical advancements and promising future prospects for Affimed N.V. (AFMD) in the biopharmaceutical industry.

Affimed NV (AFMD) reported Q3 2024 earnings call highlights focusing on navigating financial challenges. The financial challenges discussed in the earnings call may moderately influence the company's future performance.

Affimed N.V. reports third quarter 2024 financial results and pipeline updates, including completion of enrollment for AFM24 combination trial, updated clinical data for Acimtamig and AFM28, and cash runway projection into Q4 2025. The article discusses significant pipeline updates and financial results that are expected to have a major impact on Affimed N.V.'s future performance and strategic direction.

Affimed N.V. (AFMD) will report its third quarter 2024 financial results and corporate update on November 14, 2024. The financial results and corporate update may moderately influence key areas such as financial performance and competitive positioning.

Affimed N.V. announces acceptance of three abstracts at the 2024 ASH Annual Meeting, including an oral presentation highlighting advancing clinical pipeline in leukemia and lymphoma. The announcement of promising efficacy and safety data from clinical studies at a major conference is likely to have a significant impact on Affimed N.V.'s future and market performance.

683 Capital Management, LLC acquired 274,600 shares of Affimed NV at $3.12 each, increasing their total holdings to 924,600 shares. Significant investment by 683 Capital Management could have a major impact on Affimed NV's future performance and market trajectory.

Affimed N.V. reports positive results in various clinical trials for cancer treatments, including EGFR mutant lung cancer and Hodgkin Lymphoma. Financially, the company has a cash runway into H2 2025. The positive clinical trial results and financial stability are expected to have a significant impact on Affimed N.V.'s future performance and market positioning.

Affimed N.V. appoints new CEO, shares fall 6.6% on leadership change. Company's pipeline development and stock performance discussed. New CEO appointment and stock drop may moderately influence company's future operations and market performance.

Affimed N.V. appoints Shawn M. Leland as Chief Executive Officer. The appointment of a new CEO with extensive industry experience is expected to significantly impact Affimed N.V.'s future growth and corporate development.

Affimed N.V. will report second quarter 2024 financial results and corporate update on September 5, 2024. The financial results and corporate update may moderately influence key areas such as financial performance and competitive positioning.

Affimed N.V. to report Q2 earnings with focus on progress of three clinical programs for cancer indications. The article discusses potential impact on financial performance and product development.

Affimed N.V. (NASDAQ:AFMD) price target raised by Laidlaw to $25, with a potential upside of 257%. Global financial markets show volatility, Bitcoin underperforms traditional assets, Thailand's Government Pension Fund diversifies strategy, U.S. equity market sees shifts in investor focus. Laidlaw's price target raise for AFMD with significant upside potential and market volatility signals a potentially significant impact on AFMD's future and market performance.

Affimed N.V. beats earnings expectations with reported EPS of $-1.38, exceeding expectations of $-1.73. The company presents positive clinical data for all three of its programs. The positive clinical data presented by Affimed N.V. is expected to have a significant impact on the company's future performance and market positioning.

Affimed N.V. reports positive initial data from multiple clinical studies, including high response rates and promising outcomes in various cancer indications. The positive clinical data and progress in multiple programs are expected to have a significant impact on Affimed's future performance and market positioning.

Vanda Pharmaceuticals (VNDA) shares surged 24.2% after receiving an acquisition offer from Cycle Group Holdings Ltd. Affimed N.V. (AFMD) shares dropped 4.4% in the same session. The acquisition offer for Vanda and the drop in AFMD shares indicate a significant impact on future performance and market dynamics.